SLC5A2 and coronary artery disorder: SGLT2 inhibitors can improve the prognosis of CHD patients undergoing PCI and reduce the occurrence of various complications, such as acute kidney injury (26, 27), lethal ventricular arrhythmias (21), and ISR (28).